Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Sold by Platinum Investment Management Ltd.

Platinum Investment Management Ltd. decreased its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 23.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 840,052 shares of the biopharmaceutical company’s stock after selling 252,810 shares during the quarter. Platinum Investment Management Ltd.’s holdings in Esperion Therapeutics were worth $1,848,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at $606,000. Anson Funds Management LP acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at $540,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Esperion Therapeutics by 71.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 295,378 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Esperion Therapeutics by 66.8% in the third quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock valued at $995,000 after buying an additional 241,512 shares in the last quarter. Finally, Wasatch Advisors LP grew its stake in shares of Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after buying an additional 6,483,070 shares in the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR opened at $1.58 on Wednesday. The company has a market capitalization of $312.60 million, a price-to-earnings ratio of -2.47 and a beta of 1.04. The business has a 50-day moving average of $1.87 and a two-hundred day moving average of $2.08. Esperion Therapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $3.94.

Analyst Ratings Changes

Several research analysts recently commented on the company. JMP Securities reissued a “market outperform” rating and set a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, March 4th. Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday, December 13th. Finally, Cantor Fitzgerald assumed coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Esperion Therapeutics currently has a consensus rating of “Hold” and an average target price of $6.75.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.